Quidel (QDEL) and Life Technologies (LIFE) receive the FDA's 510(k) clearance to market their...


Quidel (QDEL) and Life Technologies (LIFE) receive the FDA's 510(k) clearance to market their products together for diagnosing Clostridium difficile bacterial infections (CDI), which have been linked to 14,000 deaths a year in the U.S. The Quidel product involved is its Molecular Direct C. difficile Assay and those of Life are its Real-Time PCR Instruments for monitoring hospital-acquired infections . (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs